Grünenthal completed the acquisition of Nebido from Bayer for €500m.

Grünenthal, a privately-owned pharmaceutical company, completed the acquisition of Nebido, a firm engaged in the treatment of male hypogonadism, from Bayer, a German multinational pharmaceutical and life sciences company, for €500m. “One in six men over 50 live with the symptoms of testosterone deficiency. Too few of these patients receive appropriate treatment. We are committed to facilitating access to treatment for even more patients in need. Grünenthal’s strong track record of acquiring established brands has significantly improved our profitability, allowing us to invest in research and development and create the next generation of pain therapies," Gabriel Baertschi, Grünenthal CEO.